Socazolimab(索卡佐利单抗注射液)

Socazolimab Injection is the only PD-L1 inhibitor in China that retains Antibody-Dependent Cellular Cytotoxicity (ADCC). It was included in the national breakthrough therapy designation in 2021 and first approved for marketing in China in 2023.

100mg(4ml)/vial

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Socazolimab Medication Q&A

There is no data in this category！

Seagull Health·Chinese Medicines

Socazolimab(索卡佐利单抗注射液)

Socazolimab Medication Q&A

Recommended